<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-2891</journal-id>
<journal-title><![CDATA[Revista científica ciencias de la salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. cient. cienc. salud]]></abbrev-journal-title>
<issn>2664-2891</issn>
<publisher>
<publisher-name><![CDATA[Universidad del Pacífico]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-28912023000100003</article-id>
<article-id pub-id-type="doi">10.53732/rccsalud/2023.e5102</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos adversos a las vacunas contra la COVID-19 en Paraguay en el 2021]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse effects to the vaccines against COVID-19 in Paraguay in 2021]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galeano]]></surname>
<given-names><![CDATA[Rosa Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Antúnez]]></surname>
<given-names><![CDATA[Karen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chamorro]]></surname>
<given-names><![CDATA[Olga Noemí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Recalde]]></surname>
<given-names><![CDATA[Dara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kallsen]]></surname>
<given-names><![CDATA[Johana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampos]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Norte Facultad de Ciencias Médicas ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Ministerio de Salud Pública y Bienestar Social Dirección General de Vigilancia de la Salud ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Enfermería y Obstetricia ]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>5</volume>
<fpage>3</fpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2664-28912023000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2664-28912023000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2664-28912023000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Introducción. La vacunación es una de las estrategias de salud pública más eficaces, sin embargo, puede producir efectos adversos (EA). En Paraguay, en diciembre del 2020, se lanzó el Plan Nacional de Vacunación como parte de las medidas de control y prevención contra la COVID-19, que contempla la vigilancia de eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Objetivo. Determinar los EA de las vacunas contra la COVID-19 aplicadas en el Paraguay en el 2021. Metodología. Estudio analítico transversal que incluyó una encuesta en Google Forms difundida a través de las redes sociales. Se recolectaron variables sociodemográficas, tipo de vacuna, dosis y EA. Los datos se analizaron con Epi InfoTM, y se calculó Odd Ratio (OR) con su IC95% a un nivel de significancia de &lt;0,05. Resultados. Participaron del estudio, 641 personas (edad media: 27 ± 13 años), 69% mujeres y 54% del departamento Central. El 75% recibió dos dosis de la vacuna, 56,3% presentó EA con la primera dosis y 45,7% con la segunda. La presencia de EA en la primera dosis se asoció con el sexo femenino (OR 1,73; IC95% 1,23-2,42; p=0,001) y edad menor de 30 años (OR 1,73; IC95% 1,30-2,46; p&lt;0,001); presentar EA en la primera dosis estuvo asociada a presentarlos con la segunda dosis (OR 3,84, IC95% 2,39-5,09, p&lt;0,001). Conclusión. Las reacciones adversas a las vacunas fueron frecuentes, pero leves y autolimitadas. Aquellos encuestados que presentaron EA en la primera dosis tuvieron mayor chance de volverlos a presentar en la segunda.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Introduction. Vaccine is one of the most effective public health strategies, however, it can produce adverse effects (AE). In Paraguay, in December 2020, the National Vaccination Plan was launched as part of the control and prevention measures against COVID-19, which contemplates the surveillance of events supposedly attributable to vaccination or immunization (ESAVI). Objective. to determine the AE of the vaccines against COVID-19 used in Paraguay in 2021. Methodology. Cross-sectional analytical study using Google Forms for a survey disseminated through social networks. Sociodemographic variables, type of vaccine, doses, AE were collected. Data were analyzed with Epi InfoTM, Odds Ratio was calculated with a 95% CI, at a significance level of p value &lt;0.05. Results. A total of 641 people participated in the study (mean age: 27 ± 13 years), 69% women and 54% from the Central Department. Seventy-five percent received two doses of the vaccine, 56.3% had AE with the first dose and 45.7% AE with the second. AE in the first dose was associated with females (OR 1.73 (95%CI 1.23-2.42); p=0.001) and age under 30 years old (OR 1.73; 95%CI 1.30-2.46; p &lt;0.001); presenting AEs in the first dose was associated with presenting them with the second dose (OR 3.84; 95%CI 2.39-5.09; p&lt;0.001). Conclusion. Adverse reactions to vaccines were common but mild and self-limited. Those respondents who presented AE in the first dose had a high chance of presenting them again in the second dose.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[AstraZeneca vaccine]]></kwd>
<kwd lng="es"><![CDATA[Pfizer vaccine]]></kwd>
<kwd lng="es"><![CDATA[COVID-19 Vaccines, Paraguay]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[AstraZeneca vaccine]]></kwd>
<kwd lng="en"><![CDATA[Pfizer vaccine]]></kwd>
<kwd lng="en"><![CDATA[COVID-19 Vaccines]]></kwd>
<kwd lng="en"><![CDATA[Paraguay]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Nuevo coronavirus 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Johns Hopkins University &amp; Medicine</collab>
<source><![CDATA[See the latest data in your region]]></source>
<year></year>
<publisher-name><![CDATA[Johns Hopkins Coronavirus Resource Center]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Johns Hopkins University &amp; Medicine</collab>
<source><![CDATA[COVID-19 Map]]></source>
<year></year>
<publisher-name><![CDATA[Johns Hopkins Coronavirus Resource Center]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Primer caso del nuevo coronavirus en el Paraguay]]></source>
<year>2020</year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guiñez-Coelho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guiñez-Coelho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto del COVID-19 (SARS-CoV-2) a Nivel Mundial, Implicancias y Medidas Preventivas en la Práctica Dental y sus Consecuencias Psicológicas en los Pacientes]]></article-title>
<source><![CDATA[Int J Odontostomatol]]></source>
<year>2020</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>271-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[Vacunas contra la COVID-19]]></source>
<year></year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marco]]></surname>
<given-names><![CDATA[JJG]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquín]]></surname>
<given-names><![CDATA[MJÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles]]></article-title>
<source><![CDATA[Fmc]]></source>
<year>2021</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>442-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Gobierno presenta Plan Nacional de Vacunación contra el COVID-19]]></source>
<year></year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Información sobre vacunas, Paraguay]]></source>
<year>2021</year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Vigilancia y Monitoreo de ESAVI]]></source>
<year>2021</year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Boletín epidemiológico-ESAVI]]></source>
<year></year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Mayo Clinic.org</collab>
<source><![CDATA[History of COVID-19: Outbreaks and Vaccine Timeline]]></source>
<year></year>
<publisher-name><![CDATA[Mayo Clinic]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Arriban las primeras dosis de vacunas contra el COVID-19]]></source>
<year></year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[Efectos secundarios de las Vacunas contra la COVID-19]]></source>
<year></year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Influence of Sex on Pharmacokinetics]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2003</year>
<volume>42</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>107-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zucker]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Prendergast]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in pharmacokinetics predict adverse drug reactions in women]]></article-title>
<source><![CDATA[Biol Sex Differ]]></source>
<year>2020</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Flanagan]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in immune responses]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2016</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>626-38</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elnaem]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Mohd Taufek]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Ab Rahman]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Mohd Nazar]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
<name>
<surname><![CDATA[Zin]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Nuffer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?]]></article-title>
<source><![CDATA[Vaccines]]></source>
<year>2021</year>
<volume>9</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1156</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abu-Hammad]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Alduraidi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Abu-Hammad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alnazzawi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Babkair]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Abu-Hammad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines]]></article-title>
<source><![CDATA[Vaccines]]></source>
<year>2021</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>577</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Collado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Castiñeiras Ortega]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Contreras]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[González de Abreu]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Casma López]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Núñez López]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas notificadas tras la administración de vacuna frente a Covid-19 en trabajadores de un hospital terciario]]></article-title>
<source><![CDATA[Rev Asoc Esp Espec En Med Trab]]></source>
<year>2021</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>217-28</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2020</year>
<volume>07</volume>
<numero>31</numero>
<issue>31</issue>
<page-range>20161216</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulligan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lyke]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Absalon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gurtman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lockhart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>586</volume>
<numero>7830</numero>
<issue>7830</issue>
<page-range>589-93</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Logunov]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Dolzhikova]]></surname>
<given-names><![CDATA[IV]]></given-names>
</name>
<name>
<surname><![CDATA[Shcheblyakov]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Tukhvatulin]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Zubkova]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Dzharullaeva]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10275</numero>
<issue>10275</issue>
<page-range>671-81</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<source><![CDATA[Side effect worry grows for AstraZeneca vaccine]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<source><![CDATA[Efectos adversos de la vacuna Sputnik V en Argentina: actualización luego de 436.269 dosis]]></source>
<year></year>
<publisher-name><![CDATA[Fundación Femeba]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macchia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrante]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Angeleri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Biscayart]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mariani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country]]></article-title>
<source><![CDATA[JAMA Netw Open]]></source>
<year>2021</year>
<volume>4</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
